Pharmacological Approaches for the Treatment of Obesity
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 62 (6) , 915-944
- https://doi.org/10.2165/00003495-200262060-00005
Abstract
The high incidence of obesity, its multifactorial nature, the complexity and lack of knowledge of the bodyweight control system, and the scarcity of adequate therapeutics have fuelled anti-obesity drug development during a considerable number of years. Irrespective of the efforts invested by researchers and companies, few products have reached a minimum level of effectiveness, and even fewer are available in medical practice. As a consequence of anti-obesity research, our knowledge of the bodyweight control system increased but, despite this, the pharmacological approaches to the treatment of obesity have not resulted yet in effective drugs. This review provides a panoramic of the multiple different approaches developed to obtain workable drugs. These approaches, however, rely in only four main lines of action: i) control of energy intake, mainly through modification of appetite; ii) control of energy expenditure, essentially through the increase of thermogenesis; iii) control of the availability of substrates to cells and tissues through hormonal and other metabolic factors controlling the fate of the available energy substrates; and iv) control of fat reserves through modulation of lipogenesis and lipolysis in white adipose tissue. A large proportion of current research is centred on neuropeptidic control of appetite, followed by the development of drugs controlling thermogenic mechanisms and analysis of the factors controlling adipocyte growth and fat storage. The adipocyte is also a fundamental source of metabolic signals, signals that can be intercepted, modulated and used to force the brain to adjust the mass of fat with the physiological means available. The large variety of different approaches used in the search for effective antiobesity drugs show both the deep involvement of researchers on this field and the large amount of resources devoted to this problem by pharmaceutical companies. Future trends in anti-obesity drug research follow closely the approaches outlined; however, the increasing mass of information on the molecular basis of bodyweight control and obesity will in the end prevail in our search for effective and harmless anti-obesity drugs.Keywords
This publication has 422 references indexed in Scilit:
- Inhibition of Food Intake by Central Injection of Anti-orexin Antibody in Fasted RatsBiochemical and Biophysical Research Communications, 2000
- The Novel Neuropeptide Y Y1 Receptor Antagonist J-104870: A Potent Feeding Suppressant with Oral BioavailabilityBiochemical and Biophysical Research Communications, 1999
- N-docosahexaenoyl, 3 hydroxytyramine : A dopaminergic compound that penetrates the blood-brain barrier and suppresses appetiteLife Sciences, 1996
- Apolipoprotein A‐IV: A Circulating Satiety Signal Produced by the Small IntestineObesity Research, 1995
- Sertraline and Relapse Prevention Training Following Treatment by Very‐Low‐Calorie Diet: A Controlled Clinical TrialObesity Research, 1995
- Effects of the α1-adrenergic agonist cirazoline on locomotion and brown adipose tissue thermogenesis in the ratLife Sciences, 1992
- DexfenfluramineDrugs, 1992
- Food intake suppressant effect of baclofen in ratsGeneral Pharmacology: The Vascular System, 1989
- Anorectic activities of serotonin uptake inhibitors: Correlation with their potencies at inhibiting serotonin uptake and 3H-mazindol bindingLife Sciences, 1988
- Thermogenic and anorectic effects of ephedrine and congeners in mice and ratsLife Sciences, 1982